Lab. Seminar
¾È³çÇϼ¼¿ä. À̹øÁÖ ¹ßÇ¥ÀÚ ¿µÁø ÀÔ´Ï´Ù.
Á¦°¡ ¼±Á¤ÇÑ ³í¹®Àº 2020³â Nature Communications¿¡ ÃâÆǵÈ
" PD-1 pathway regulates ILC2 metabolism and PD-1 agonist treatment ameliorates airway hyperreactivity " ÀÔ´Ï´Ù.
PD-1 inhibitory axis´Â ´Ù¾çÇÑ ¸é¿ª¹ÝÀÀÀ» Á¶ÀýÇϴ°ÍÀ¸·Î ¾Ë·ÁÁ®ÀÖ½À´Ï´Ù.
ÇØ´ç ³í¹®¿¡¼´Â lung inflammation »óȲ¿¡¼ lung ILC2°¡ ¹ßÇöÇÏ´Â PD-1ÀÌ ¾î¶² ±â´ÉÀ» ÇÏ´ÂÁö È®ÀÎÇÏ¿´½À´Ï´Ù.
PD-1 deficiency ILC2´Â metabolic shift°¡ ÀϾ¸ç proliferation ¹× asthmaÁõ»ó¿¡µµ ¿µÇâ ÁÖ´Â °ÍÀ» Áõ¸íÇÏ°í,
ILC2°¡ ¹ßÇöÇÏ´Â PD-1ÀÌ asthma Áõ»óÀ» Á¶ÀýÇϴµ¥ ÇÙ½ÉÀûÀÎ ¿ªÇÒÀ» ÇÒ ¼ö ÀÖÀ½À» ½Ã»çÇÏ°í ÀÖ½À´Ï´Ù.
ÇöÀç ÁøÇàÇÏ°í ÀÖ´Â ÀúÀÇ ¿¬±¸¿¡ Àû¿ë/Âü°íÇÒ Á¡ÀÌ ¸¹¾Æ ÇØ´ç ³í¹®À» ¼±Á¤ÇÏ¿´½À´Ï´Ù.
¿½ÉÈ÷ ÁغñÇÏ¿© Åä¿äÀÏ¿¡ ºË°Ú½À´Ï´Ù.
°¨»çÇÕ´Ï´Ù.
Æò¿µÁø ¿Ã¸²
¹ßÇ¥ ³í¹® ¸µÅ©:
https://www.nature.com/articles/s41467-020-17813-1
- ´ÙÀ½±Û
- 2/26 ¹ßÇ¥³í¹®ÀÔ´Ï´Ù.
- / °ü¸®ÀÚ
- ¾È³çÇϼ¼¿ä. À̹ø ÁÖ Åä¿äÀÏ ¼¼¹Ì³ª ¹ßÇ¥ÀÚ ÀÎȯÀÔ´Ï´Ù.
Á¦°¡ À̹ø ÁÖ ¹ßÇ¥µå¸± ³í¹®Àº 2018³âµµ Immunity¿¡ Ãâ°£µÈ 'Commensals Suppress Intestinal Epithelial Cell Retinoic Acid Synthesis to Regulate Interleukin-22 Activity and Prevent Microbial Dysbiosis'ÀÔ´Ï´Ù.
ÀÌ ³í¹®¿¡¼´Â Àå³» comm..
- ÀÌÀü±Û
- 2/12 ¹ßÇ¥³í¹®ÀÔ´Ï´Ù.
- / °ü¸®ÀÚ
- ¾È³çÇϼ¼¿ä, À̹øÁÖ ¹ßÇ¥ÀÚ ´ÙÁ¤ÀÔ´Ï´Ù.
Á¦°¡ À̹ø¿¡ ¼±Á¤ÇÑ ³í¹®Àº 2019³â JEM¿¡ ÃâÆǵÈ,
'IL-27 promotes the expansion of self-renewing CD8+ T cells in persistent viral infection'ÀÔ´Ï´Ù.
À§ ³í¹®Àº ÃÖ±Ù¿¡ Á¤Àdz»·ÁÁø chronic infection µ¿¾È¿¡ ƯÀÌÀûÀ¸·Î ¹ßÇöÇÏ´Âmemory-like CXCR5+CD8+..
QUICK
MENU
TOP